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Adamantane-resistant inﬂ  uenza A is an emerging prob-
lem, but infections caused by resistant and susceptible vi-
ruses have not been compared. We identiﬁ  ed adamantane 
resistance in 47% of 152 inﬂ  uenza A virus (H3N2) isolates 
collected during 2005. Resistant and susceptible viruses 
caused similar symptoms and illness duration. The preva-
lence of resistance was highest in children.
D
uring the past 4 decades, antiviral drug therapy has 
been a useful strategy for both prophylaxis and treat-
ment of inﬂ  uenza A (1,2). The most widely used drugs have 
been 2 adamantane derivatives (amantadine and rimanta-
dine), which are effective for prophylaxis and reduce ill-
ness duration if started within 48 hours after symptom on-
set (3,4). These drugs block the M2 ion channel protein, 
preventing viral replication (5). From 1997 through 2004, 
few inﬂ  uenza A (H3N2) isolates were resistant to adaman-
tanes, although resistance among isolates from Asia in-
creased substantially in 2003 (6). In the United States, the 
proportion of inﬂ  uenza A (H3N2) isolates with adamantane 
resistance was 0.8%–2.2% during this period and 11% in 
the 2004–05 inﬂ  uenza seasons. However, in the 2005–06 
season, >90% of inﬂ  uenza A (H3N2) isolates from patients 
in 26 states contained a mutation conferring resistance to 
adamantane drugs (7). 
Ferret models suggest that virulence is not increased 
by adamantane resistance in inﬂ  uenza A (H3N2) infections 
(8), although experimental studies with recombinant inﬂ  u-
enza (H1N1) in mice have suggested that the mortality rate 
is increased by a double mutation conferring adamantane 
resistance (9). Little is known regarding clinical effects in 
humans infected with adamantane-resistant inﬂ  uenza virus-
es. We compared clinical and demographic characteristics 
of patients infected with either adamantane-susceptible or 
-resistant strains of inﬂ  uenza A during the 2004–05 season.
The Study
Study participants were derived from a study of inﬂ  u-
enza vaccine effectiveness conducted within a 14–Zip code 
region surrounding Marshﬁ  eld, Wisconsin, during Janu-
ary–March 2005. Eligible participants included children 
6–23 months of age, adults >65 years of age, and persons 
24 months–64 years of age with a high-risk medical condi-
tion. Research coordinators recruited eligible patients and 
obtained samples for inﬂ  uenza culture during inpatient and 
outpatient encounters for acute respiratory illness. Each 
participant (or parent) completed a short interview form to 
assess symptoms and onset date, and culture-conﬁ  rmed pa-
tients were contacted again to determine the illness recov-
ery date. The study was approved by the Marshﬁ  eld Clinic 
institutional review board, and all participants provided 
written informed consent.
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Figure. Results of patient recruitment and inﬂ  uenza cultures. *One 
isolate was not characterized.
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Inﬂ  uenza virus was isolated by inoculation and incuba-
tion in monolayered rhesus monkey kidney cells. Cultures 
were examined for cytopathic effect, and cultures showing 
no cytopathic effect were tested twice for hemagglutina-
tion titers. Inﬂ  uenza A and B were conﬁ  rmed by immuno-
ﬂ  uorescence (Chemicon International, Inc., Temecula, CA, 
USA). All inﬂ  uenza A isolates were tested for adamantane 
resistance at the Centers for Disease Control and Preven-
tion (CDC). Procedures for RNA extraction and pyrose-
quencing have been previously described (7). A medical 
record review was performed to assess any use of antiviral 
drugs by inﬂ  uenza A patients from 60 days before through 
14 days after the enrollment date.  
Univariate comparisons were performed, and crude 
and adjusted prevalence ratios were computed to evaluate 
the association between adamantane resistance and age, 
gender, vaccination status, date of clinical encounter, and 
presence of a high-risk medical condition. Enrollment dates 
were grouped into 4 consecutive 3-week periods beginning 
January 3, 2005. The referent period was the second 3-
week period when the number of inﬂ  uenza cases peaked. 
All analyses were conducted with SAS version 9.1 (SAS 
Institute Inc., Cary, NC, USA).
Inﬂ  uenza virus was isolated in 167 (20%) of 818 cul-
tures from ill cohort members; 153 (92%) were inﬂ  uenza A 
(H3N2) and 14 (8%) were inﬂ  uenza B (Figure). Inﬂ  uenza 
A (H1N1) was not isolated from any patients. Adaman-
tane resistance was present in 72 (47%) of 152 inﬂ  uenza 
A isolates; 1 additional isolate was not characterized. All 
resistant isolates contained a point mutation resulting in a 
serine to asparagine change at amino acid 31 (S31N) of the 
M2 protein. The median age was 43.6 years among patients 
with resistant isolates and 64.7 years among those with 
susceptible isolates (p = 0.002). The proportion of patients 
with adamantane-resistant viruses was signiﬁ  cantly higher 
in 6- to 23-month-old children (70%) compared with adults 
>65 years of age (39%) (unadjusted prevalence ratio 1.8; 
95% conﬁ  dence interval [CI] 1.2–2.6; p = 0.003). 
Number of symptoms and duration of illness were 
similar for patients with adamantane-resistant and -sus-
ceptible inﬂ  uenza isolates (Table 1). The proportion of 
patients hospitalized was nearly the same in each group, 
Table 1. Clinical features of patients with adamantane-resistant or -susceptible influenza A, 2004–05 season 
Clinical feature
Adamantane-resistant 
influenza, n = 72
Adamantane-susceptible 
influenza, n = 80 p value*
Median duration of illness† 12 days 13 days 0.96
No. (%) hospitalized 7 (10) 9 (12) 0.74
No. (%) fully recovered at time of follow-up interview 63 (88) 65 (81) 0.29
Median no. symptoms‡ 9 8 0.59
No. (%) receiving antiviral treatment§  15 (21) 31 (39) 0.02
Median time from symptom onset to healthcare encounter  3 days 2 days 0.34
Single symptom, no. (%)‡ 
  Fever 34 (69) 52 (74) 0.56
  Cough 48 (98) 68 (97) 0.78
  Headache 41 (84) 53 (76) 0.29
  Muscle pain 37 (76) 45 (64) 0.57
  Nasal congestion 40 (82) 54 (77) 0.55
  Hoarseness 35 (71) 55 (79) 0.37
  Fatigue 45 (92) 66 (94) 0.72
  Ear pain 16 (33) 24 (34) 0.85
  Sore throat 29 (59) 40 (57) 0.82
  Difficulty breathing 28 (57) 35 (50) 0.44
  Wheezing 25 (51) 42 (60) 0.33
  Nausea 16 (33) 27 (39) 0.51
   Vomiting 10 (20) 9 (13) 0.27
  Diarrhea 12 (24) 15 (21) 0.70
  Rash 2 (4) 2 (3) 1.00
Combined symptoms, no. (%)‡
  Fever and cough 33 (67) 52 (74) 0.41
  Fever and headache 31 (63) 43 (61) 0.84
  Fever, cough, and headache 30 (61) 43 (61) 0.98
  Fever and muscle pain 29 (59) 39 (56) 0.71
  Fever, headache, and muscle pain 27 (55) 35 (50) 0.58
  Fever, headache, muscle pain, and cough 26 (53) 35 (50) 0.74
*χ
2, Fisher exact, or Wilcoxon rank sum tests performed as appropriate. 
†Based on 128 influenza A patients who had recovered fully at the time of follow-up interview.  
‡Children 6 to 23 months of age were excluded from the numerator and denominator for symptoms. 
§One patient had received antiviral treatment prior to influenza culture. 
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fer signiﬁ  cantly.  Forty-ﬁ   ve patients received antiviral 
therapy (37 adamantanes, 8 oseltamivir), but only 1 was 
treated with amantadine before inﬂ  uenza culture was ob-
tained. Clinical features and duration of illness were simi-
lar whether or not patients received adamantane therapy. 
In a multivariable model that included patients of all ages, 
adamantane resistance was not associated with gender, 
time of clinical encounter, or inﬂ  uenza vaccination status 
(Table 2). Children 6–23 months old without a high-risk 
medical condition were signiﬁ  cantly more likely to be in-
fected with adamantane-resistant inﬂ  uenza A than were 
adults >65 years of age who had a high-risk condition. In 
a secondary analysis, no association was found between 
adamantane resistance and number of symptoms, duration 
of illness, or hospitalization. 
Conclusions
This study provides epidemiologic evidence that the 
point mutation (S31N) conferring adamantane resistance 
has not altered inﬂ  uenza A (H3N2) virulence as measured 
by clinical symptoms and duration of illness. Hospitaliza-
tion rates were also similar, although the power to detect a 
difference was low. These results are consistent with prior 
research in ferrets, which demonstrated that virulence was 
similar for adamantane-resistant and -susceptible inﬂ  uenza 
A (H3N2) isolates (8). The source population for this study 
included persons who were eligible for inﬂ  uenza vacci-
nation based on age group or the presence of a high-risk 
medical condition. Consequently, participants were more 
likely to experience inﬂ  uenza complications relative to the 
general population. The absence of any difference in clini-
cal severity in this higher risk population provides some re-
assurance that adamantane resistance will not affect overall 
inﬂ  uenza morbidity. 
Factors contributing to rapid emergence of adaman-
tane-resistant inﬂ  uenza viruses are not fully known. Resis-
tance has been observed in a variety of outbreak and insti-
tutional settings for many years (10–12) but did not spread 
into the general population until recently (6,7). The propor-
tion of human inﬂ  uenza A (H3N2) isolates with adaman-
tane resistance increased dramatically in People’s Republic 
of China and Taiwan in 2003 (6). However, the degree to 
which the spread of resistant viruses from Asia contributed 
to the rapid escalation of adamantane resistance in the Unit-
ed States is uncertain. 
The 2004–05 inﬂ  uenza season provided an opportunity 
to learn more about the epidemiology of adamantane resis-
tance during a period when drug resistance was increasing 
in Wisconsin but was not yet universal. Children had the 
highest risk of acquiring an adamantane-resistant inﬂ  uenza 
infection and are an important reservoir for transmission of 
inﬂ  uenza to adult household members and the community 
(13). Still, we cannot explain why children were preferen-
tially infected with adamantine-resistant strains in 2004–
05. Only 1 patient was treated with amantadine before en-
rollment. The higher prevalence of resistance in children 
was therefore not attributable to individual adamantane 
use. There may have been multiple introductions of ada-
mantane-resistant inﬂ  uenza viruses from other geographic 
areas during the 2004–05 season. This phenomenon was 
described in a recent phylogenetic analysis of inﬂ  uenza A 
Table 2. Demographic features of patients with adamantine-resistant or -susceptible influenza A, 2004–05 season* 
Variable
No. (%) resistant 
isolates, n = 72
No. (%) susceptible 





Age and high-risk status†
  6–23 mo without high risk 20 (74.1) 7 (25.9) 2.0 (1.3–3.0) 2.1 (1.4–3.1)
  6–23 mo with high risk 3 (50.0) 3 (50.0) 1.3 (0.6–3.2) 1.4 (0.5–3.5)
  2–17 y with high risk 8 (61.5) 5 (38.5) 1.7 (0.9–2.9) 1.4 (0.8–2.4)
  18–49 y with high risk 7 (36.8) 12 (63.2) 1.0  (0.5–2.0) 0.9 (0.5–1.9)
  50–64 y with high risk 8 (38.1) 13 (61.9) 1.0 (0.5–2.0) 1.0 (0.6–1.9)
>65 y without high risk 7 (46.7) 8 (53.3) 1.3 (0.7–2.4) 1.2 (0.7–2.3)
>65 y with high risk 19 (37.2) 32 (62.8) Referent group Referent group
Sex
  Male 37 (50.7) 36 (49.3) 1.1 (0.8–1.6) 1.1 (0.8–1.5)
  Female 35 (44.3) 44 (55.7) Referent group Referent group
Dates of clinical encounter
  2005 Jan 3–23 10 (47.6) 11 (52.4) 0.9 (0.5–1.4) 0.9 (0.5–1.5)
  2005 Jan 24–Feb 13 44 (55.0) 36 (45.0) Referent period Referent period
  2005 Feb 14–Mar 6 15 (35.7) 27 (64.3) 0.6 (0.4–1.0) 0.6 (0.4–1.0)
  2005 Mar 7–25 3 (33.3) 6 (66.7) 0.6 (0.2–1.6) 0.5 (0.2–1.3)
Received 2004–05 influenza vaccine? 
  Yes 45 (42.9) 60 (57.1) 0.7 (0.5–1.0) 0.8 (0.6–1.1)
  No 27 (57.4) 20 (42.6) Referent group Referent group
*CI, confidence interval. 
†For the multivariate model, a composite variable was created based on age and the presence or absence of a high-risk medical condition as defined by 
Advisory Committee on Immunization Practices criteria.  
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Adamantane-Resistant Inﬂ  uenza(H3N2) isolates from New York state over a 9-year period 
(14). The analysis suggested that viral evolution within 
epidemic seasons is dominated by random importation of 
distinct viral strains from other geographic areas. 
CDC continues to recommend that adamantane drugs 
not be used for inﬂ  uenza treatment in the United States. 
Given the recent emergence of oseltamivir-resistant inﬂ  u-
enza A and B infections (15,16), ongoing monitoring of in-
ﬂ  uenza virus susceptibility to adamantanes and neuramini-
dase inhibitors is essential.
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